Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Onychomycosis is a common nail disease that is often chronic, difficult to eradicate, and has a tendency to recur. The most common oral therapies for dermatophyte toenail onychomycosis include terbinafine, itraconazole and fluconazole. OBJECTIVES: A cumulative meta-analysis of the randomized controlled trials (RCTs) for antimycotic agents was performed to determine whether the pooled estimate of the cure rates has remained consistent over the years. Furthermore, for each agent we compared the overall meta-analytical average of both mycological and clinical response rates of RCTs vs. open studies. METHODS: We searched MEDLINE (1966 to November 2002) for relevant studies evaluating the efficacy of the oral antifungal agents terbinafine, itraconazole (pulse or continuous), fluconazole and griseofulvin for treating dermatophyte toenail onychomycosis. Studies included in this meta-analysis required a standard accepted dosage regimen, treatment duration and follow-up period. To determine the cumulative meta-analytical average, studies were sequentially pooled by adding one study at a time according to the date of publication (i.e. earliest to the most recent). RESULTS: There were 36 studies included in the analyses. For RCTs the change in efficacy of mycological cure rates from the first trial to the overall cumulative meta-average for each drug comparator is as follows (with 95% confidence interval): terbinafine, 78 +/- 6% (n = 2 studies, 79 patients) to 76 +/- 3% (n = 18 studies, 993 patients) (P = 0.68); itraconazole pulse, 75 +/- 10% (n = 1 study, 20 patients) to 63 +/- 7% (n = 6 studies, 318 patients) (P = 0.25); itraconazole continuous, 63 +/- 5% (n = 1 study, 84 patients) to 59 +/- 5% (n = 7 studies, 1131 patients) (P = 0.47); fluconazole, 53 +/- 6% (n = 1 study, 72 patients) to 48 +/- 5% (n = 3 studies, 131 patients) (P = 0.50); and griseofulvin, 55 +/- 8% (n = 2 studies, 109 patients) to 60 +/- 6% (n = 3 studies, 167 patients) (P = 0.41). The cumulative meta-analytical average of mycological cure rates when comparing RCTs vs. open studies was: terbinafine, 76 +/- 3% (n = 18 studies, 993 patients) vs. 83 +/- 12% (n = 2 studies, 391 patients) (P = 0.0028); itraconazole pulse, 63 +/- 7% (n = 6 studies, 318 patients) vs. 84 +/- 9% (n = 3 studies, 194 patients) (P = 0.0001); and fluconazole, 48 +/- 5% (n = 3 studies, 131 patients) vs. 79 +/- 3% (n = 3 studies, 208 patients) (P = 0.0001). CONCLUSIONS: The cumulative meta-analysis of cure rates for RCTs suggests that over time, as new RCTs have been conducted, the efficacy rates have remained consistent. The efficacy rates of open studies are substantially higher compared with RCTs and may therefore overestimate cure rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Antifungal agents: An overview. Part I
Gupta, A. K., Sauder, D. N., & Shear, N. H. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81495-8 · Cited by 369
Self-citationThe Importance of Quality of Primary Studies in Producing Unbiased Systematic Reviews
Khan, K. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.6.661 · Cited by 328
Evans, E. G. V., & Sigurgeirsson, B. (1999) · BMJ · doi:10.1136/bmj.318.7190.1031 · Cited by 263
Sigurgeirsson, B., Ólafsson, J. H., Steinsson, J. Þ., Paul, C., Billstein, S., & Evans, E. G. V. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.3.353 · Cited by 212
Doncker, P. D. (1996) · Archives of Dermatology · doi:10.1001/archderm.132.1.34 · Cited by 155
Scher, R. K., Breneman, D., Rich, P., Savin, R. C., Feingold, D. S., Konnikov, N., Shupack, J. L., Pinnell, S., Levine, N., Lowe, N. J., et al. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70490-6 · Cited by 146
Bräutigam, M., Nolting, S., Schopf, R. E., & Weidinger, G. (1995) · BMJ · doi:10.1136/bmj.311.7010.919 · Cited by 143
Backer, M. D., de Keyser, P., Vroey, C. D., & Lesaffre, E. M. E. H. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb15653.x · Cited by 132
Backer, M. D., Vroey, C. D., Lesaffre, E. M. E. H., Scheys, I., & de Keyser, P. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70486-4 · Cited by 113
Oral Treatments for Toenail Onychomycosis
Crawford, F., Young, P. J., Godfrey, C., Bell-Syer, S. E., Hart, R. L. D., Brunt, E. M., & Russell, I. T. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.6.811 · Cited by 90
OPEN RANDOMIZED COMPARISON OE ITRACONAZOLE VERSUS TERBINAEINE IN ONYCHOMYCOSIS
Arenas, R., Domínguez‐Cherit, J., & Fernández, L. M. P. (1995) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1995.tb03600.x · Cited by 80
Treatment of onychomycosis with terbinafine
Baudraz-Rosselet, F., Rakosi, T., Wili, P. B., & Kenzelmann, R. (1992) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1992.tb00009.x · Cited by 73
Korting, H. C., Schäfer-Korting, M., Zienicke, H., Georgii, A., & Ollert, M. W. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.10.2064 · Cited by 67
Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials
Haugh, M., Helou, S., Boissel, J., & Cribier, B. J. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04825.x · Cited by 66
Intermittent Therapy with Terbinafine for Dermatophyte Toe‐Onychomycosis: A New Approach
Alpsoy, E., Yılmaz, E., & Başaran, E. (1996) · The Journal of Dermatology · doi:10.1111/j.1346-8138.1996.tb04009.x · Cited by 62
Fluconazole in the treatment of onychomycosis caused by dermatophytes
Kuokkanen, K. E., & Alava, S. (1992) · Journal of Dermatological Treatment · doi:10.3109/09546639209088703 · Cited by 57
Appraising Systematic Reviews and Meta-analyses
Bigby, M., & Williams, H. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.6.795 · Cited by 51
Doncker, P. D., Lint, J. V., Dockx, P., & Roseeuw, D. I. (1995) · PubMed · Cited by 50
Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study
Assaf, R. R., & Elewski, B. E. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90327-8 · Cited by 48
Degreef, H. J. (1999) · Acta Dermato Venereologica · doi:10.1080/000155599750011020 · Cited by 47
Terbinafine versus itraconazole: A controlled clinical comparison in onychomycosis of the toenails
Bräutigam, M. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70485-2 · Cited by 43
Arca, E., Taştan, H. B., Akar, A., Kurumlu, Z., & Gur, A. (2002) · Journal of Dermatological Treatment · doi:10.1080/09546630252775171 · Cited by 41
Meta-analysis for combining Bayesian probabilities
Velanovich, V. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90232-n · Cited by 31
Ladhani, S. N., & Williams, H. C. (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02315.x · Cited by 23
Cited by
REVIEW ARTICLE: Toenail onychomycosis: an important global disease burden
Thomas, J., Jacobson, G. A., Narkowicz, C. K., Peterson, G. M., Burnet, H., & Sharpe, C. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01107.x · Cited by 327
Clarke, M., Brice, A., & Chalmers, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102670 · Cited by 120
Tinea Unguium: Diagnosis and Treatment in Practice
Asz-Sigall, D., Tosti, A., & Arenas, R. (2017) · Mycopathologia · doi:10.1007/s11046-016-0078-4 · Cited by 36
Metadata
- Authors
- Gupta, A. K., Ryder, J. E., & Johnson, A. M.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-03
- Volume
- 150
- Issue
- 3
- Pages
- 537-544
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2095370280
- Cited by
- 163
- References
- 26
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.